The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis - PubMed (original) (raw)
. 1997 Aug 1;159(3):1437-43.
D A Arenberg, J P Lynch 3rd, R I Whyte, M D Iannettoni, M D Burdick, C A Wilke, S B Morris, M C Glass, B DiGiovine, S L Kunkel, R M Strieter
Affiliations
- PMID: 9233641
The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis
M P Keane et al. J Immunol. 1997.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic and often fatal disorder. Fibroplasia and deposition of extracellular matrix are dependent, in part, on angiogenesis. We postulated that an imbalance exists in the expression of angiogenic (IL-8) vs angiostatic (IFN-gamma-inducible protein (IP-10)) CXC chemokines, which favors net angiogenesis in IPF. To test this hypothesis, we obtained open lung biopsies either from normal patients undergoing thoracic surgery for reasons other than interstitial lung disease (control) or from patients with IPF. We found that levels of IL-8 were greater from tissue specimens of IPF patients then from those of controls. In contrast, IP-10 levels were higher from tissue specimens obtained from control subjects than from those from IPF patients. When IL-8 or IP-10 was depleted from IPF tissue specimens, tissue-derived angiogenic activity was markedly reduced or enhanced, respectively. Immunolocalization of IL-8 demonstrated that the pulmonary fibroblast (PF) of IPF lung was the predominant cellular source of IL-8. Isolated PF from IPF patients constitutively produced more IL-8 and less IP-10 than control PF. Conditioned media from IPF-PFs demonstrated constitutive angiogenic activity that was attributable, in part, to IL-8. Depletion of IP-10 from IPF-PF CM resulted in an increase in corneal neovascularization. These findings support the notion that IL-8 and IP-10 are important factors that regulate angiogenic activity in IPF.
Similar articles
- IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis.
Keane MP, Belperio JA, Arenberg DA, Burdick MD, Xu ZJ, Xue YY, Strieter RM. Keane MP, et al. J Immunol. 1999 Nov 15;163(10):5686-92. J Immunol. 1999. PMID: 10553099 - ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis.
Keane MP, Belperio JA, Burdick MD, Lynch JP, Fishbein MC, Strieter RM. Keane MP, et al. Am J Respir Crit Care Med. 2001 Dec 15;164(12):2239-42. doi: 10.1164/ajrccm.164.12.2104106. Am J Respir Crit Care Med. 2001. PMID: 11751193 - Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis.
Keane MP, Belperio JA, Moore TA, Moore BB, Arenberg DA, Smith RE, Burdick MD, Kunkel SL, Strieter RM. Keane MP, et al. J Immunol. 1999 May 1;162(9):5511-8. J Immunol. 1999. PMID: 10228032 - [Recent advances on the role of chemokines/chemokine receptors in the pathogenesis of idiopathic pulmonary fibrosis].
Brunetti G, Pignatti P. Brunetti G, et al. Recenti Prog Med. 2007 Feb;98(2):90-6. Recenti Prog Med. 2007. PMID: 17439069 Review. Italian. - CXC chemokines in angiogenesis.
Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM. Belperio JA, et al. J Leukoc Biol. 2000 Jul;68(1):1-8. J Leukoc Biol. 2000. PMID: 10914483 Review.
Cited by
- Associations of circulating matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases with clinically relevant outcomes in idiopathic pulmonary fibrosis: Data from the IPF-PRO Registry.
Amubieya O, Todd JL, Neely ML, Kaner RJ, Lasky JA, Namen A, Hesslinger C, Palmer SM, Weigt SS, Belperio JA. Amubieya O, et al. PLoS One. 2024 Oct 17;19(10):e0312044. doi: 10.1371/journal.pone.0312044. eCollection 2024. PLoS One. 2024. PMID: 39418259 Free PMC article. - Stem cell-based therapy for fibrotic diseases: mechanisms and pathways.
Taherian M, Bayati P, Mojtabavi N. Taherian M, et al. Stem Cell Res Ther. 2024 Jun 18;15(1):170. doi: 10.1186/s13287-024-03782-5. Stem Cell Res Ther. 2024. PMID: 38886859 Free PMC article. Review. - Multiscale computational model predicts how environmental changes and drug treatments affect microvascular remodeling in fibrotic disease.
Leonard-Duke J, Agro SMJ, Csordas DJ, Bruce AC, Eggertsen TG, Tavakol TN, Barker TH, Bonham CA, Saucerman JJ, Taite LJ, Peirce SM. Leonard-Duke J, et al. bioRxiv [Preprint]. 2024 Mar 22:2024.03.15.585249. doi: 10.1101/2024.03.15.585249. bioRxiv. 2024. PMID: 38559112 Free PMC article. Preprint. - Role of Sensory Nerves in Pulmonary Fibrosis.
Norton CE. Norton CE. Int J Mol Sci. 2024 Mar 21;25(6):3538. doi: 10.3390/ijms25063538. Int J Mol Sci. 2024. PMID: 38542511 Free PMC article. Review. - Pulmonary fibrosis in sarcoidosis.
Asif H, Ribeiro Neto M, Culver D. Asif H, et al. Sarcoidosis Vasc Diffuse Lung Dis. 2023 Sep 13;40(3):e2023027. doi: 10.36141/svdld.v40i3.14830. Sarcoidosis Vasc Diffuse Lung Dis. 2023. PMID: 37712364 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical